Drug firm Divis Laboratories today reported a 8.73 per cent rise in standalone net profit to Rs 268.32 crore for the quarter ended December 31, 2016.
The company had posted a net profit of Rs 246.76 crore in the year-ago period, Divis Laboratories said in a filing to BSE.
Its total income from operations also rose to Rs 976.48 crore during the quarter under review from Rs 859.75 crore during the same period a year ago.
The company’s Unit-II at (its plant) in Visakhapatnam had an inspection by the USFDA from November 29, 2016 to December 6, 2016. It received form 483 with 5 observations at the closure of the inspection, Divis Laboratories said.
“The company has filed its comprehensive response to the observations of USFDA within the stipulated time,” it added.
Review of its response by the USFDA is awaited, it said.